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Abstract
Background: 5-hydroxytryptamine (5 HT, serotonin) is one of the key neuromodulators in
mammalian brain, but many fundamental properties of serotonergic neurones and 5 HT release
remain unknown. The objective of this study was to generate an adenoviral vector system for
selective targeting of serotonergic neurones and apply it to study quantal characteristics of 5 HT
release in the rat brain.
Results: We have generated adenoviral vectors which incorporate a 3.6 kb fragment of the rat
tryptophan hydroxylase-2 (TPH-2) gene which selectively (97% co-localisation with TPH-2) target
raphe serotonergic neurones. In order to enhance the level of expression a two-step
transcriptional amplification strategy was employed. This allowed direct visualization of
serotonergic neurones by EGFP fluorescence. Using these vectors we have performed initial
characterization of EGFP-expressing serotonergic neurones in rat organotypic brain slice cultures.
Fluorescent serotonergic neurones were identified and studied using patch clamp and confocal
Ca2+  imaging and had features consistent with those previously reported using post-hoc
identification approaches. Fine processes of serotonergic neurones could also be visualized in un-
fixed tissue and morphometric analysis suggested two putative types of axonal varicosities. We
used micro-amperometry to analyse the quantal characteristics of 5 HT release and found that
central 5 HT exocytosis occurs predominantly in quanta of ~28000 molecules from varicosities and
~34000 molecules from cell bodies. In addition, in somata, we observed a minority of large release
events discharging on average ~800000 molecules.
Conclusion: For the first time quantal release of 5 HT from somato-dendritic compartments and
axonal varicosities in mammalian brain has been demonstrated directly and characterised. Release
from somato-dendritic and axonal compartments might have different physiological functions.
Novel vectors generated in this study open a host of new experimental opportunities and will
greatly facilitate further studies of the central serotonergic system.
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Background
Animal and human studies have associated the serotoner-
gic (5 HTergic) system with diseases such as depression
and anxiety [1-3], or schizophrenia [4,5]. Drugs which
modulate 5 HT re-uptake are widely used for treatment of
depression and the range of their clinical applications is
expanding [6,7].
Surprisingly little is known about the neurobiology of
central 5 HTergic neurones because these cells are inter-
mingled with other cellular phenotypes even in nuclei
where their density is highest. Hence, while numerous
experimental and clinical studies point to 5 HT release
and uptake as highly medically relevant processes [6,8], it
has been impossible to directly study these processes at
single cell level. In recent years, targeted expression of
genes to selective cellular phenotypes has become a pop-
ular strategy for studies of brain function. We reasoned
that a method for selective gene expression and manipu-
lation in 5 HTergic neurones would be extremely useful
for understanding the mechanisms by which 5 HT exerts
its actions. Indeed, even an ability to directly visualize 5
HTergic neurones live within the highly heterogeneous
cell milieu of the brain would offer a whole host of oppor-
tunities for electrophysiological, imaging, amperometry
and other studies [9].
Two strategies may be used for selective targeting – germ-
line transgenesis or viral vectors. Both approaches rely on
the use of a cell-specific promoter (CSP) which is able to
drive cell type-specific transgene expression. Transgenic
mice have been developed where the enhancer region of
the transcription factor Pet-1 was used to drive either Cre-
recombinase (Cre) or yellow fluorescent protein expres-
sion in 5 HTergic neurones [10,11]. Using Pet-1 for
expressing Cre in mice with floxed allele of another tran-
scription factor, Lmx1b, it is possible to selectively sup-
press 5 HTergic neurones in mice [12,13]. These mice
models are a valuable resource suitable for some types of
experiments. For a number of years several groups have
been pursuing a different strategy, namely using viral vec-
tors for gene expression in selected cellular groups in the
brain [14-18]. One great advantage of viral transgenesis is
that it is independent of the animal strain, for instance the
same vector has been used to visualise catecholaminergic
neurones in normo- and hypertensive rats [19]. Moreover,
as critical sequences in promoters seem to be highly con-
served, the same CSPs usually work equally well cross-spe-
cies. For example, the synapsin-1 (SYN) promoter which
is commonly used for viral gene expression in rodent
studies was originally cloned from human DNA [16], and
the human and mouse promoter sequences of glial fibril-
lary acidic protein are active and cell-specific in both rats
and mice [18,20]. Therefore, with viral vectors, specific
gene manipulation becomes possible in various normal
and mutant lines of rats, mice and probably many other
species. This becomes particularly relevant in research
areas where rat models are of critical value, for example in
anxiety-and depression-related studies [21,22]. Viral vec-
tors are also highly versatile, easily transferable between
laboratories and relatively inexpensive to produce. Finally
and importantly, because the viral vectors can be applied
to the postnatal tissue, it is possible to achieve much
higher levels of transgene expression than with any stand-
ard germline transgenic approach without the risk of
embryonic toxicity.
We set out to develop a viral vector system for selective tar-
geting of central 5 HTergic neurones. First, we explored
the regions upstream of the coding sequence for tryp-
tophan hydroxylase-2 (TPH-2), the key enzyme in central
neuronal 5 HT synthesis [23] and found 2 kb – 3.6 kb of
the promoter region to confer selective expression to
raphe 5 HTergic neurones [24]. Because these sequences
were insufficiently powerful to drive visible expression of
a fluorescent marker such as enhanced green fluorescent
protein (EGFP) we potentiated CSP using a two-step tran-
scriptional amplification (TSTA) strategy [24-27]. This
strategy is based on simultaneous cell-specific expression
of artificial transcriptional enhancers and their unique
binding domains which are placed upstream of a weak
CSP [20,27,28].
The lentiviral vector (LVV) generated in our previous
study [24] will be a valuable resource, predominantly for
in vivo experimentation on the 5 HTergic system. How-
ever, for many types of in vitro experiments, adenoviral
vectors (AVV) are preferable since they are much more
efficient in slice cultures and cheap to generate in large
quantities [15]. The objective of the current study was
therefore two-fold. First, building on the success of our
previous work, we set out to generate a TSTA-amplified
AVV system for specific targeting 5 HTergic neurones in
organotypic slice cultures in vitro. Second, we applied this
system to obtain the first information about the character-
istics of quantal 5 HT release from 5 HTergic neurones of
mammalian brain.
Results
The ability to visualize 5 HTergic neurones in living brain
tissue preparations, rather than via post-hoc immunohis-
tochemical identification or other less direct means of
phenotype verification opens a wide range of opportuni-
ties for investigation of cellular physiology and signalling
properties of these cells. Organotypic brain slice cultures
transduced with AVV are excellent models for confocal
imaging and electrophysiological experiments [15,29,30].
Previously, we have successfully used this approach for
studies of GABAergic and catecholaminergic neurones in
the brainstem [17,19,31].BMC Biotechnology 2009, 9:23 http://www.biomedcentral.com/1472-6750/9/23
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In our recent study, we used LVV in vivo to determine
those regions upstream of the TPH-2 coding sequence
which confer 5 HTergic neurone-specific expression [24].
TSTA-amplified 3.6 kb promoter region (3.6 TPH)
resulted in visible EGFP fluorescence in living 5 HTergic
neurones which was nearly 100% specific in the brain-
stem areas tested. Due to the size of 3.6 TPH in relation to
AVV capacity (<8 kb), in this study, we decided to use the
two-promoter-copy strategy incorporated into two sepa-
rate AVV (Figure 1 see [24]. We previously used similar
two-vector approaches, e.g. [20,28] and know that trans-
duced cells take up multiple copies of the viral genomes,
which ensures that both parts of the system are in place.
In the present experiments we employed AVV-G4BS-
3.6TPH-EGFP and AVV-3.6TPH-GAL4|p65 to transduce
brainstem slice cultures. Similar to the corresponding LVV
described in [24], the dual AVV system demonstrated high
specificity. 97% of EGFP-expressing neurones in slice cul-
tures were also TPH-2-positive (estimate based on n~700
cells from 20 slice cultures from 4 separate preparations;
Figure 2A–B). Fluorescence was clearly detectable after 2 –
3 days and reached an apparent plateau after 6–7 days.
Several dozens of fluorescent neurones could be visual-
ised in each healthy slice. We did not evaluate the dura-
tion of expression in this study but from our previous
experience with AVV carrying CSP it is likely to last for the
duration of the life of the slice culture. No EGFP fluores-
cence was evident in cultures transduced with AVV
3.6TPH-EGFP alone. Not only cell somata, but also
numerous axons with characteristic varicosities could be
visualized (Figure 2C). High power confocal stacks of
images of living EGFP-expressing varicosities were col-
lected and analyzed post-hoc. The absolute majority of
living 5 HTergic varicosities (92% of 106 measured) were
elongated (average aspect ratio 1.46) along the axonal axis
and very small (median ~1.5 μm along the long axis; Fig-
ure 2C–D). Interestingly, there was also a distinct minor-
ity population (~10%) of larger varicosities with medial
length ~4 μm (Figure 2C–D, red arrows).
To confirm that the EGFP-expressing 5 HTergic cells were
healthy, whole-cell patch clamp recordings were obtained
from median raphe neurones using the same approach as
in our previous studies [17,19] (Figure 3). The patch
pipette contained the red-shifted Ca2+ indicator Rhod-2
(Figure 3A, Additional file 1). Cells had membrane poten-
tials in the range of -55 to -60 mV (n = 8, not corrected for
the junction potential), and responded to positive current
injections with barrages of action potentials. These were
usually followed by long after-hyperpolarizations (Figure
3B–C), consistent with previous reports for raphe 5 HTer-
gic neurones identified by post-hoc methods [32,33]. As
expected, intracellular [Ca2+] increased when the cells
Binary AVV system based on 3.6 TPH promoter and TSTA Figure 1
Binary AVV system based on 3.6 TPH promoter and TSTA. In this design, the first AVV utilises 3.6 TPH to express 
the chimeric recombinant transcriptional enhancer, GAL4|p65. The second AVV contains the actual transgene under control of 
the 3.6 TPH promoter but with G4BS (multimerised GAL4 binding sites) fused to its 5' end. Binding of the enhancer to these 
sites strongly potentiates the expression of EGFP.
3.6TPH
Enhancer cassette
GAL4|p65 Transgene 
(EGFP)
G4BS 3.6TPH
Transgene cassette
+++++BMC Biotechnology 2009, 9:23 http://www.biomedcentral.com/1472-6750/9/23
Page 4 of 11
(page number not for citation purposes)
Figure 2 (see legend on next page)
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were induced to fire bursts of action potentials (Figure
3C).
Vesicular release of oxidizable transmitters can be
detected with micro-amperometry, an electrochemical
technique which employs positively charged carbon fiber
microelectrodes placed adjacent to release sites [31]. Oxi-
dation spikes (Figure 4A–B), consistent with exocytotic
release of 5 HT, were detected at fluorescently labeled var-
icosities and cell bodies of 5 HTergic neurones. The fre-
quency of release events was low (average 0.01 Hz and
0.03 Hz for varicosities and somata, respectively). At vari-
cosities, events had a median quantal size of ~18 fC, with
a median amplitude of ~5 pA and duration at half-height
of 3.1 msec (Figure 4C; 106 events from 5 release sites). At
somatic release sites, the majority of events (97%) fol-
lowed a similar distribution to varicosities, with a slightly
higher median quantal content (~22 fC) and similar size
and kinetics (~5 pA; 3.5 ms; 114 events in 5 recordings;
Figure 4C). However, in addition, a few larger events were
observed with a quantal content higher than 200 fC (aver-
age ~500 fC). Putative foot-like events, which are com-
monly interpreted as signs of partial fusion, were observed
in less than 3% of events.
Discussion
Most central 5 HTergic fibres originate from neurones
concentrated within two clusters located close to the mid-
line: a caudal group of the midline raphe nuclei, and a
more rostral group that includes the dorsal and median
raphe nuclei [34,35]. Raphe nuclei are often referred to as
5 HTergic but, in fact comprise a variety of neurochemical
phenotypes. For example, both dorsal and medial raphe
nuclei give rise to a glutamatergic projection towards the
hippocampal formation [36] and glutamatergic neurones
are intermingled with the TPH-2-positive cells which send
their axons towards the same targets. Physiological roles
of these parallel connections are very hard to disentangle
without the help of new molecular tools such as the vec-
tors described here. Interestingly, a generic "neuronal"
promoter synapsin-1 is not suitable for targeting 5 HTer-
gic neurones as the majority of the cells which expressed
EGFP in animals injected with LVV-SYN-EGFP were non-
TPH-positive [24]. Importantly, in slice cultures, vectors
have access to any part of the brain tissue in contrast to in
vivo micro-injections when their specificity (or lack of it)
outside of the transduced area may remain unnoticed. The
present results demonstrate that when AVV are applied in
vitro they drive gene expression in 5 HTergic cells of vari-
ous groups with very high specificity.
Because conventional AVV cannot incorporate very large
transcriptional control units, we decided to place the
TSTA-boosted 3.6 TPH promoter system into two separate
rather than a single vector. Based on previous experience,
we reasoned that the dual AVV system would function
efficiently and greatly simplify vector design, leaving a
generous capacity within the second vector. Here we only
expressed EGFP, but in principle this system can easily
accommodate larger transgenes such as bi-cistronic con-
structs or protein fusions.
EGFP fluorescence in present experiments was sufficient
not only to visualize cell somata, but to reveal all the intri-
cate detail of the 5 HTergic neurones' structure including
axonal varicosities. From our earlier estimates [37], we
believe that many EGFP-fluorescent 5 HTergic neurones
expressed ~1 μM of EGFP. This for the first time made it
possible to estimate the dimensions of living varicosities
without the potential artefacts of fixation. Interestingly,
we observed two distinct peaks in the size distribution of
varicosities: the majority with a median size of approxi-
mately 1.5 × 1 μm and a minority category which is
approximately 3 times larger. Whether these two popula-
tions of varicosities are functionally different is an intrigu-
ing question which needs to be addressed in future
studies.
Selective EGFP expression in raphe 5 HTergic neurons in organotypic slice cultures Figure 2 (see previous page)
Selective EGFP expression in raphe 5 HTergic neurons in organotypic slice cultures. A. Confocal images from slice 
cultures of the dorsal raphe after transduction with the dual AVV system (AVV-G4BS-3.6TPH-EGFP and AVV-3.6TPH-
GAL4p65) and immunostained for TPH-2 (centre panels). EGFP expression (left panels) was 5 HT-selective (overlay of green 
and red channel – right panels) and sufficiently potent for single-cell experiments on live 5 HTergic neurones. Middle row of 
images in a higher power image of the upper one. Lower row of images is from a different slice, closer to the ventral edge 
(white dotted line). Yellow dashed line in upper raw shows approximate midline. B. Distribution of EGFP-expressing 5 HTergic 
neurones in a midbrain slice culture. Left panel – EGFP fluorescence, right panel – overlay of fluorescence channel on the DIC 
image. Yellow arrow points at the edge of the aqueduct. Cells are largely located along midline (B7/B8 groups), some more lat-
eral cells probably come from B9 group. C. Characteristic varicosities of EGFP-expressing 5 HTergic axons. Note that varicos-
ities are predominantly small but few of a larger type can also be observed (red arrow). D. Morphometric analysis of living 5 
HTergic varicosities (n = 106) in slice cultures. The histogram shows the distribution of varicosity lengths measured along the 
axis of the axon. While the majority of varicosities were small (1.5–2 μm) there was a distinct sub-population of larger varicos-
ities (median ~4 μm, red arrow). Large varicosities are rare, but could represent a specific functional phenotype.BMC Biotechnology 2009, 9:23 http://www.biomedcentral.com/1472-6750/9/23
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Patch clamp and imaging of intracellular [Ca2+] in 5 HTergic neurones in slice culture Figure 3
Patch clamp and imaging of intracellular [Ca2+] in 5 HTergic neurones in slice culture. A. Confocal image of 
EGFP-positive ventral raphe neurones (left panel), one of which was recorded in whole-cell configuration using a pipette solu-
tion containing Rhod-2 (centre panel; arrow indicates pipette tip). B. Representative recording from an EGFP-positive raphe 
neuron. Trains of action potentials (top trace) were triggered by injections of depolarizing current (lower trace). Note the 
prominent after-hyperpolarizations (arrowheads). C. Intracellular Ca2+ dynamics in a 5 HTergic neuron based on Rhod-2 fluo-
rescence (top trace; fluorescence intensity in arbitrary units, AU). Repeated trains of action potentials (bottom trace) induced 
by current injections resulted in reproducible [Ca2+] increases.
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Microamperometric analysis of 5 HT release in raphe slice culture Figure 4
Microamperometric analysis of 5 HT release in raphe slice culture. A. Amperometric trace from an EGFP-expressing 
varicosity during an active episode. Spike-like events of varying sizes are visible. Note that the noise level looks exaggerated at 
this time scale due to low frequency baseline variability. B. Examples of amperometric spikes of various quantal sizes which 
were detected at 5 HTergic varicosities. C. Quantal size distribution of release events at 5 HTergic varicosities and cell bodies. 
At somata, several large release events, outside of the main population, were observed.
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Functionally, EGFP-expressing 5 HTergic neurones had
features consistent with what could be anticipated based
on various previous studies where post-hoc immunohis-
tochemistry or similar approaches were used. As shown in
Fig. 3, these cells have healthy resting and action poten-
tials, generate evident after-hyperpolarisations following
a train of spikes and their intracellular Ca2+  readily
increases in response to stimulation. Thus, AVV do not
have any evident detrimental effects on the transduced
cells which survive in slice cultures for several weeks.
Although it was generally accepted that varicosities are the
critical sites of 5 HT release, quantal characteristics of 5 HT
release in the brain were previously unknown. By placing
micro-amperometric electrodes on fluorescently identi-
fied cell compartments, we were able to collect initial
information about this process. We found that 5 HT, alike
central noradrenaline [31], is released by exocytosis not
only from axonal varicosities but also from neuronal cell
bodies. Because release from soma and dendrites occurs in
the 5 HTergic nucleus itself while axonal release is directed
towards the targets in remote brain areas it is tempting to
speculate that the mechanisms which control release from
these compartments could differ. Central 5 HT exocytosis
occurred predominantly in quanta estimated at ~28000
molecules from varicosities and ~34000 molecules from
cell bodies. In addition, in somata we observed a minority
of large release events discharging on average ~800000
molecules. These categories of release events were compa-
rable to the ones we previously recorded from central cat-
echolaminergic neurones, as were their time courses [31].
However, the quantal sizes of 5 HT release were smaller
than those of central catecholamine release. Also, frequen-
cies of exocytotic events were markedly lower for 5 HT
than for noradrenaline. Quantal release of 5 HT has been
previously detected amperometrically from leech Retzius
neurones [38,39] where two populations of release
events, with average 5 HT discharge of 4700 and 80000
molecules, were postulated. Since these populations are
consistent with release from the two different varieties of
vesicles found in Retzius cells, namely small clear and
large dense core vesicles (diameters ~40 nm and 90 nm
based on ultrastructural data), 5 HT was suggested to be
stored at intravesicular concentrations of around 0.27 M
in both vesicle types [38,39].
Similar to Retzius cells, populations of small clear and
large dense core vesicles (diameters ~40 nm and 100 nm,
respectively) have been shown in central 5 HTergic and
catecholaminergic neurones in the rat [40,41]. We found
no convincing amperometric evidence for 5 HT release
from a population of small clear vesicles. However, iden-
tification of some of the smallest release events could have
been prevented by the noise limitations of our system.
The main population of small release events in the rat
raphe could represent release from large dense core vesi-
cles, which should be either slightly smaller than in the
leech (diameter ~70 nm versus ~100 nm), or contain a
lower 5 HT concentration (0.1 M versus 0.27 M). Interest-
ingly, the diameter of large dense core vesicles in leech
somata was ~15% larger than in axons [39]. If the same
applies to rat central 5 HTergic neurones, this could
explain why our somatic events were ~7% larger than
those recorded at the varicosities. For the very large 5 HT
release events documented here, a morphological corre-
late remains to be found.
In terms of future directions, one evident path to explore
is to express light-activated ion channels ChR2 and NpHR
in 5 HTergic neurones [42,43] in order optically control
their activity. Vectors may be constructed to express not
only a fluorescent marker, but a functional gene, for
example a 5 HT transporter. Although here we only
describe in vitro applications of these novel AVV, they can
also be used in vivo. An interesting property of AVV which
we found in previous experiments with noradrenergic
cells, is their ability to transduce cells via the retrograde
route [9]. Because both, 5 HTergic and noradrenergic neu-
rones have varicose un-myelinated axons, it may be possi-
ble that sub-groups of 5 HTergic neurones can be
transduced by injecting AVV into their target areas. It
would also be extremely interesting to see whether these
AVV are suitable for targeting 5 HTergic neurones in other,
non-rodent species.
Conclusion
We have generated novel TSTA-amplified AVV suitable for
selective gene expression in raphe 5 HTergic neurons of
rodents and obtained the first key facts about quantal
release of 5 HT in the brain. Numerous avenues are now
open for further inquiries into the physiology of central 5
HTergic neurons and the mechanisms of action of drugs,
such as blockers of 5 HT uptake, a widely used group of
anti-depressants.
Methods
Construction of TPH-2 promoter-containing viral vectors
As described previously, lead promoter fragments were
PCR amplified from the sequences 5' relative to the tran-
scriptional initiation site of the rat brain TPH-2 gene, and
inserted upstream of EGFP into a LVV shuttle plasmid
[24]. These vectors also incorporated elements of TSTA.
LVV were tested in vivo using microinjection into the rat
raphe and from these experiments it was concluded that
3.6 TPH (promoter sequence starting 3.6 kb upstream of
the coding region of the TPH-2 gene) drives highly specific
and visible EGFP expression in 5 HTergic neurons in vivo
[24]. In order to maximise space for expression cassettes,
we placed the components of the TSTA system into two
separate viral particles. To this end, the expression cas-BMC Biotechnology 2009, 9:23 http://www.biomedcentral.com/1472-6750/9/23
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settes from the LVV shuttle plasmids pTYF-G4BS-3.6TPH-
EGFP and pTYF-3.6TPH-GAL4|p65 were first transferred
into the AVV shuttle plasmid, pXCX-Sw-linker, using SceI
sites [44]. AVV were then produced by homologous
recombination of shuttle and the helper plasmid pBHG10
in HEK293 cells. The media was collected for subsequent
rounds of AVV proliferation in HEK293 cells until cyto-
pathic effects were achieved. AVV were purified using CsCl
gradient protocols [45]. Titers were established using an
immunoreactivity spot assay as described previously [44].
Viral vector transduction of dorsal raphe 5 HTergic 
neurons in organotypic slice cultures: Morphology, 
electrophysiology, electrochemistry
Organotypic coronal slice cultures of the rat pons/mid-
brain containing the raphe nuclei were prepared accord-
ing to previously published protocols (thickness at the
time of plating 250 μm) [15]. They were transduced with
a mixture of AVV-G4BS-3.6TPH-EGFP and AVV-3.6TPH-
GAL4|p65 at equivalent titers of ~2 × 10^8 TU/ml (2 × 10
μl of viral stock diluted into 1 ml of plating media) at the
time of plating [15]. Cultures were used between 7 and 10
days in vitro when AVV-mediated EGFP expression was
fully established. Imaging experiments were carried out at
33°C in a tissue chamber mounted on a Leica-SP2 confo-
cal microscope. Amperometric recordings were carried out
under similar conditions in a chamber based on a conven-
tional inverted fluorescent microscope (Leica).
For morphometric studies Image Pro Plus (Media Cyber-
netics) software was used. Individual varicosities which
could be clearly identified on confocal images taken from
living tissue were processed to identify varicosities and
obtain their dimensions.
Whole-cell patch clamp recordings in combination with
confocal measurement of intracellular [Ca2+] changes
were performed as described previously [17,19]. Rhod-2
was used as a Ca2+ indicator to avoid spectral interference
with EGFP.
Microamperometric recordings with carbon fibre elec-
trodes manufactured in house were performed at a driving
voltage of +800 mV, and analyzed as previously described
[19,31]. Quantal sizes (Q in Coulomb) were derived from
event integrals, and converted into the number of oxi-
dized molecules by the equation [molecules = (Q ×
Avogadro's number)/n × Faraday constant), where n, the
number of electrons transferred during oxidation of one
transmitter molecule, is 4 for 5 HT [31,38,46].
Immunohistochemistry
To assess the specificity of expression, slice cultures were
immunostained for TPH-2. First, cultures were fixed on
their membranes in 4% formaldehyde for 20 min,
removed from the membrane and incubated in 10%
horse serum with 0.3% triton in PBS for 1 hour. After
washing 3× with PBS, the sections were treated with 50%
ethanol for 30 minutes, and washed 3× for 30 minutes in
0.1 M PBS. They were then incubated for 72 hrs at 4°C in
primary mouse monoclonal anti-TPH-2 antibody (Sigma,
dilution 1:500), 5% horse serum and 0.3% triton in PBS.
This step was followed by an overnight incubation with
secondary donkey anti-mouse Alexa594 (Invitrogen,
1:300) and 2% horse serum. To ensure complete EGFP
visualization, sections were counterstained with primary
rabbit anti-EGFP antibody (Invitrogen, 1:2000), followed
by an overnight incubation in the secondary donkey anti-
Rabbit Biotin-SP-conjugated F(ab')2 IgG (Jackson Immu-
noResearch, 1:500) and then in avidin-FITC for 4 hours.
Sections were washed between incubations 3× for 30 min
in PBS. Stained sections were mounted using Vectashield
(Vector Labs), cover-slipped and imaged with a confocal
microscope (Leica SP1) at 488 nm and 543 nm excitation
for green and red channels, respectively. Channels were
imaged sequentially using either 488 or 543 nm excitation
to prevent "bleed" of the fluorescence between them.
Abbreviations
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